In an article published in the March 24, 2026, issue of ILCN, Haleigh Behrman presented a study conducted by Christopher Seder, MD, of 48,779 patients with clinically node-negative non-small cell lung cancer (NSCLC) who had varying degrees of lymph node dissection (LND) based on analysis of the STS database, presented at the annual meeting of the Association of Thoracic Surgeons. The assessment of multiple N1 nodal stations—specifically intrapulmonary stations (12–14)—led to an increased nodal upstaging rate of 11.2%. This clinical evidence warrants a comprehensive evaluation of current lymph node dissection paradigms in NSCLC, extending well beyond a simple reassessment of hilar LND margins.

Accurate assessment of lymph node involvement is critical, as it often reclassifies cancer stage, directly influencing therapeutic decisions and patient outcomes.1 The extent of dissection—ranging from complete radical lymphadenectomy to selective or lobe-specific sampling—continues to be debated as early-stage NSCLC detected by screening rises. Systematic dissection involves the removal of a predetermined set of lymph nodes to ensure thorough pathological assessment.

While this has traditionally been the standard approach, growing evidence suggests it may lead to increased postoperative complications. The ACOSOG Z0030 trial demonstrated that mediastinal lymph node sampling offers comparable overall and disease-free survival to complete lymphadenectomy in early-stage NSCLC.

Although full dissection identified occult N2 disease in an additional 4% of patients, it did not significantly reduce recurrence rates. The findings establish systematic sampling as a safe, less invasive alternative to extensive dissection when rigorous intraoperative assessment is performed.2

Okada et al. reported a complication rate of 17.3% with systematic dissection compared to 10.1% for lobe-specific techniques, with arrhythmias being a notable concern.3 Meta-analyses indicate that lobe-specific dissection yields comparable, or even superior, overall survival (HR 0.80) without significantly affecting recurrence-free survival (HR 0.96).4 This more selective method seeks to prevent unnecessary lymph node removal, reducing operative trauma and preserving long-term quality of life.

Globally, practices vary based on institutional protocols, surgeon experience, and patient characteristics. The European Society of Thoracic Surgeons recommends dissecting at least three mediastinal and three hilar lymph nodal stations for reliable staging. The National Comprehensive Cancer Network (NCCN) advises evaluating a minimum of three mediastinal (N2) stations, while the American Thoracic Society’s “3N2+ 1N1” standard requires assessing at least one N1 (hilar or intrapulmonary) and three N2 stations. These guidelines reflect efforts to balance thorough staging with surgical safety.4,5,6

The primary debate lies in systematic versus selective dissection approaches. Systematic dissection enhances staging accuracy but may carry higher risks of bleeding, chylothorax, prolonged operative time, pneumonia, and transient neurological deficiency due to nerve injury. As early-stage lung cancers become increasingly common, the risks of extensive dissection may outweigh the benefits, particularly for small or minimally invasive tumors.7

Tumor size and histology strongly influence nodal spread: smaller adenocarcinomas, especially those arising from ground-glass or part-solid lesions, show very low rates of mediastinal or hilar metastasis. The necessity of extensive LND for indolent tumors with low invasive potential remains controversial.8

Every thoracic surgeon is familiar with the nature of lymphadenectomy, particularly when performed using the VATS technique. Meeting the requirements regarding both the number of lymph node stations removed and the qualitative aspects—specifically the need to excise the node intact, without breaching its capsule—is challenging. However, technological advances are further reshaping this discussion. Robotic-assisted thoracic surgery has introduced greater precision and improved visualization during lymph node dissection. Randomized trials, including RAVAL, ROMAN, and RVLob, demonstrate that robotic approaches reduce intraoperative complications while maintaining oncologic thoroughness. Consequently, adopting a safer approach to LND in different tumor subtypes prompts a reevaluation of traditionally rigid standards.9

Ongoing controversy over lymph node dissection demands a modernized paradigm in lung cancer surgery. Today, screening-driven detection frequently reveals early-stage, slow-growing, or non-solid lesions with lepidic features. Given their exceptionally low risk of lymph node metastasis, shifting toward a tailored lymphadenectomy is strongly justified. Such a balanced approach limits extensive dissection for subsolid lesions with less than a 50% solid component or ground-glass morphology, while maintaining rigorous nodal assessment for solid tumors (or even strengthening the strategy for N1 dissection—at least in some institutional protocols).

References

• 1. Jing T, Yang J, Wei X, Wang C and Li B (2025) Balancing oncological control and immune preservation in the immunotherapy era: revisiting lymph node dissection in non-small cell lung cancer. Front. Oncol. 15:1652551. doi: 10.3389/fonc.2025.1652551
• 2. Darling G, Allen M, Decker P, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. The Journal of Thoracic and Cardiovascular Surgery, 141, 662-670.
• 3. Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. Ann Thorac Surg. 2006 Mar;81(3):1028-32. doi: 10.1016/j.athoracsur.2005.09.078. PMID: 16488715.
• 4. Woo W, Shin JI, Kipkorir V, Yang YH, Lee S, Lee CY. Clinical Benefits of Lobe-Specific Lymph Node Dissection in Surgery for NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep. 2023 Apr 10;4(5):100516. doi: 10.1016/j.jtocrr.2023.100516. PMID: 37214413; PMCID: PMC10199215.
• 5. Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, Zielinski M, Lerut T, Weder W. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006 Nov;30(5):787-92. doi: 10.1016/j.ejcts.2006.08.008. Epub 2006 Sep 12. PMID: 16971134.
• 6. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: non-small cell lung cancer. Available online: https://www.nccn.org/professionals/physician_gls/default.aspx#site; 2020.
• 7. Nissen AP, Vreeland TJ, Teshome M, Archer MA, Francescatti AB, Katz MHG, Hunt KK, Zheng L, Mullett TW. American College of Surgeons Commission on Cancer Standard for Curative-intent Pulmonary Resection. Ann Thorac Surg. 2022 Jan;113(1):5-8. doi: 10.1016/j.athoracsur.2021.05.051. Epub 2021 Jun 10. PMID: 34119494.
• 8. Jiang C, Zhang Y, Fu F, Deng P, Chen H. A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer. J Thorac Oncol. 2024 Jan;19(1):25-35. doi: 10.1016/j.jtho.2023.09.1443. Epub 2023 Sep 23. PMID: 37748691.
• 9. Patel AJ and Bille A (2024) Lymph node dissection in lung cancer surgery. Front. Surg. 11:1389943. doi: 10.3389/fsurg.2024.1389943